Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis

Quanwei Zhou †, Xuejun Yan ‡, Weidong Liu ‡, Wen Yin †, Hongjuan Xu ‡, Damei Cheng ‡, Xingjun Jiang †† and Caiping Ren †,‡

† Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China, ‡ Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China, †† The NHC Key Laboratory of Carcinogenesis and The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha, China

Diffuse glioma is one of the most prevalent malignancies of the brain, with high heterogeneity of tumor-infiltrating immune cells. However, immune-associated subtypes of diffuse glioma have not been determined, nor has the effect of different immune-associated subtypes on disease prognosis and immune infiltration of diffuse glioma patients. We retrieved the expression profiles of immune-related genes from The Cancer Genome Atlas (TCGA) (n = 672) and GSE16011 (n = 268) cohorts and used them to identify subtypes of diffuse glioma via Consensus Cluster Plus analysis. We used the limma, clusterProfiler, ESTIMATE, and survival packages of R for differential analysis, functional enrichment, immune and stromal score evaluation respectively in three subtypes, and performed log-rank tests in immune subtypes of diffuse glioma. The immune-associated features of diffuse glioma in the two cohorts were characterized via bioinformatic analyses of the mRNA expression data of immune-related genes. Three subtypes (C1–3) of diffuse glioma were identified from TCGA data, and were verified using the GSE16011 cohort. We then evaluated their immune characteristics and clinical features. Our mRNA profiling analyses indicated that the different subtypes of diffuse glioma presented differential expression profile of specific genes and signal pathways in the TCGA cohort. Patients with subtype C1, who were mostly diagnosed with grade IV glioma, had poorer outcomes than patients with subtype C2 or C3. Subtype C1 was characterized by a higher degree of immune cell infiltration as estimated by GSVA, and more frequent wildtype IDH1. By contrast, subtype C3 included more grade II and IDH1-mutated glioma, and was associated with more infiltration of CD4+ T cells. Most subtype C2 had the features between subtypes C1 and C3. Meanwhile, immune checkpoints and their ligand molecules, including PD1/PD-L1/PDL2, CTLA4/CD80/CD86), and B7H3/TLT2, were significantly upregulated in subtype C1 and downregulated in subtype C3. In addition, patients with subtype C1 exhibited more frequent gene mutations. Univariate and multivariate Cox regression analyses revealed that diffuse glioma subtype was an effective, independent, and better prognostic factor. Therefore, we established a novel immune-related classification of diffuse glioma, which provides potential immunotherapy targets for diffuse glioma.

Keywords: diffuse glioma, immune checkpoint molecule, tumor immune infiltration, bioinformatic analysis, The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), immune-associated subtype
INTRODUCTION

Diffuse glioma is by far the most prevalent type of primary central nervous system (CNS) malignant tumor, which accounts for >60% of all primary brain tumors (1). The 2016 World Health Organization (WHO) Classification of CNS tumors categorizes diffuse gliomas into WHO grades II, III, and IV glioma, including oligodendroglialomas, astrocytomas, oligoastrocytomas, and glioblastomas multiforme (GBMs). Almost all glioma patients, particularly those with GBM, exhibit recurrence despite being treated with the standard treatment consisting of maximal-safety surgical resection coupled with radiotherapy and chemotherapy (2, 3). The prognosis of patients with diffuse glioma varies significantly depending on the tumor grade, with median survival ranging from 1 to 15 years (4). GBM is one of the most aggressive tumors, with a median survival of approximately 14 months (5). By contrast, patients with grade II or III glioma have a relatively better prognosis, with a median survival of >7 years (6); however, with frequent disease progression, grade II–III gliomas recur as tumors with higher grades and become resistant to therapy (7). So far, traditional treatments alone have not improved patient prognosis, and novel treatment strategies for patients with diffuse glioma are warranted.

Studies have shown that the complexity of the tumor microenvironment can be attributed to diverse immune cells. Glioma cells have been shown to recruit a variety of tumor-infiltrating immune cells, including macrophages, myeloid suppressor cells, dendritic cells, neutrophils, T and B lymphocytes, and natural killer (NK) cells, into the tumor microenvironment (8, 9). In addition, the tumor microenvironment plays a crucial role in glioma progression (10), and is associated with clinical outcomes (11). As a critical component of the complex microenvironment, tumor-infiltrating immune cells play a vital role in inhibiting or promoting tumor progression (12). Both inter- and intratumoral heterogeneity of the immediate immune microenvironments are associated with differences in the number and type of immune cells, thus representing a significant obstacle to the treatment of diffuse glioma.

The distinct immune environment of the CNS should be considered in glioma patients scheduled for immunotherapy (13) because the blood–brain barrier shields the tumor cells from conventional treatments. Nonetheless, glioma proliferation can damage the blood–brain barrier, allowing the entry of tumor-related immune cells into the tumor tissue and establishment of an immunosuppressive state in glioma. The unique CNS environment may lead to development of resistance against immunotherapy in glioma cells. To address this problem, immune checkpoint inhibitors have been developed and these checkpoint inhibitors have shown superior clinical efficacy against various tumor types. Programmed death-1 (PD-1), an immune checkpoint protein, is significantly upregulated in tumor-infiltrating immune cells (14). The PD-1 receptor expressed on the surface of CD8⁺ T-cells binds to PD-L1 on the tumor cell surface, thereby inactivating the host T-cell immune responses. Theoretically, blocking the binding of PD-L1 to PD-1 should reverse their immune suppressive effect in tumors. Pembrolizumab, a humanized monoclonal antibody against PD-1, inhibits T-cell inactivation rather than recruiting T cells to infiltrate tumor (15). One study indicates that pembrolizumab is more effective in treating tumors with a large number of infiltrating T cells as compared to tumors with lower abundance of T cells (15). Furthermore, evidence has shown that the efficacy of immunotherapy varies considerably among individuals because of inter- and intratumoral heterogeneity of the immune microenvironment. Therefore, novel classification and treatment modalities based on immune profiles are required for patients with diffuse gliomas. In the present study, we utilized The Cancer Genome Atlas (TCGA) database to identify three consensus immune-associated subtypes (C1–3) of diffuse glioma by clustering analyses based on the expression of 2,498 immune-associated genes. We then analyzed their immune characteristics and clinical features and revealed significant differences in gene signatures, signaling pathways, immune infiltration, expression of immune checkpoint genes, and clinical outcomes of these cases. Moreover, univariate and multivariate Cox regression analyses indicated that the identified subtype classification is an effective independent prognostic factor.

MATERIALS AND METHODS

Data Sources and Data Processing

High-throughput RNA sequencing (RNA-seq) data (n = 703), information on somatic mutations (MAF files) (n = 1,090), and clinical data (n = 1,105) from patients with diffuse gliomas were downloaded from TCGA (https://tcga-data.nci.nih.gov/tcga/). Two RNA-seq datasets, TCGA-lower grade glioma (LGG) and TCGA-GBM, were merged into a single metadataset, and batch effects were removed by applying the ComBat function in the SVA package of the R software (16). In the TCGA cohort, 677 samples, including five nontumor samples, 249 grade II samples, 262 grade III samples, and 161 grade IV samples, were selected from 703 cases by averaging the values from the same patient and excluding some samples. The GSE16011 dataset, involving 268 samples, was downloaded from database Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/gds/) (17). In addition, tumor mutational burden (TMB) and mutation counts were computed from somatic mutation frequencies. Sixteen samples with outlying values were excluded by means of the “outliers” package of R.

Identification of Subtypes Based on Immune-Related Genes in Diffuse Glioma

We retrieved a list of 2,498 immune-related genes from ImmPort (https://www.immport.org/), a publicly available immunology data resource. Expression profiles of the immune-related genes were obtained by mining of TCGA and GSE16011 data and were used to identify diffuse glioma subtypes via Consensus Cluster Plus analysis (17). Before identifying the subtypes, we excluded genes not expressed in >80% of the samples, resulting in 1,106 candidate genes for cluster analysis. Consensus clustering was performed using the K-means algorithm with 1,000 resampling...
iterations by random selection of a group of the samples and the most variant probe sets (80%). The optimal cluster number was determined using the consensus matrix (CM) and CDF curves of the consensus score. T-distributed stochastic neighbor embedding (t-SNE) decreased the dimensionality of the features and was employed to validate the subtype assignment by means of mRNA expression data corresponding to immune-related genes (18).

**Differential Analysis and Comparative Functional Enrichment Analysis of the Subtypes**

For each subtype, subtype-specific genes were identified by comparing the samples in a given subtype with the remaining samples using the “limma” package of R (19, 20). The cutoff criteria for differentially expressed genes were defined as false discovery rate (FDR) <0.05 and absolute log2 FC (fold change) >1. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes among diffuse glioma subtypes was performed using the clusterProfiler package (21). We selected the top 50 significant immune-related genes with the largest log2 FC in each subtype as molecular markers of immune-associated subtypes.

**Estimation of Immune-Cell Abundance**

We first compared immune and stromal scores evaluated in the three subtypes by means of the ESTIMATE package of R, which can calculate the abundance of stromal and immune cells (22). Relative abundance of 28 immune cell types in the tumor microenvironment was evaluated by gene set variation analysis (GSVA), which can estimate the scores of signaling pathways or signatures based on transcriptomic data (23). We retrieved the gene list corresponding to each immune cell type from a recent publication (24). Next, differential analysis of the relative abundance of 28 immune cell types was performed using the limma package of R, and the immune cells with absolute log2 FC >1 (FDR < 0.05) were defined as subtype-specific immune cells. Furthermore, we determined differences in the abundance of activated CD8+ T cells, activated dendritic cells, activated CD4+ T cells, neutrophils, NK cells, and macrophages in the validation cohort. After that, we calculated the abundance of immune cells using the CIBERSORT algorithm from the Tumor Immune Estimation Resource (TIMER) online database (cistrome.shinyapps.io/timer) (25, 26).

**Survival Analysis**

We excluded the samples with <30 days of overall-survival data and with missing values of clinical features in the TCGA and GSE16011 datasets. Kaplan–Meier survival curves were plotted to estimate survival distributions for each subtype in the TCGA and GSE16011 datasets. We performed the log-rank test to assess the significance of differences between the identified subtypes using the survival package in R (27). Univariate Cox and backward stepwise multivariate Cox regression analyses were performed to identify independent prognostic factors among the following variables: age, gender, tumor grade, IDH status, and chromosome 1p/19q codeletion status. P < 0.05 indicated statistical significance.

**Statistical Analysis**

Unpaired Student’s t test was performed to compare two groups with normally distributed variables, while for comparisons of multiple groups, one-way analysis and Kruskal–Wallis tests of variance were conducted as parametric and nonparametric methods, respectively. Contingency variables were analyzed using the x^2 or Fisher’s exact tests. Pearson’s correlation coefficient was determined to assess the correlation between TMB and the mRNA expression of PD-1 and PD-L1 as well as between TMB and the abundance of immune cells. All statistical analyses were performed in GraphPad Prism v.7.0 or R (v.3.6.0, https://www.r-project.org/). A two-tailed P value <0.05 was considered significant.

**RESULTS**

**Identification of Three Subtypes in Diffuse Glioma**

We mined 1,106 candidate immune-related genes from TCGA-LGG and TCGA-GBM cohorts and clustered them into three diffuse glioma subtypes. We utilized Consensus Cluster Plus to identify the different subtypes (K = 2, 3, 4, 5, and 6) among 672 diffuse glioma samples. The optimal division (k = 3) was selected as the optimal number of clusters based on the CM and CDF curves of the consensus score (Figures 1A, B). At K = 3, the boundary of the CM heatmap remained relatively clear-cut, implying that the sample cluster was stable and robust. To validate the assignment of the subtypes, t-SNE was performed to decrease dimensionality. It was confirmed that two-dimensional t-SNE distribution patterns were robustly consistent with the subtype clustering (Figure 1C). This result implied that the three clusters of samples were successfully separated from each other. We then verified these three subtypes identified in TCGA cohort using the GSE16011 dataset as described above (Figure 1D). Using the previously mentioned K = 3 classification, we uncovered significant prognostic differences in TCGA cohort (log-rank test P < 0.0001, Figure 1E), with shorter median survival for subtype C1 (n = 92, median survival: 406 days) than for subtypes C2 (n = 374, median survival: 1,762 days, P < 0.001) and C3 (n = 163, median survival: 3,200 days, P < 0.001). Patients with diffuse glioma subtype C2 showed shorter median survival than patients with subtype C3 (log-rank test, P < 0.01; Figure 1E). These findings are consistent with the differences in survival among the three subtypes in the GSE16011 dataset (Figure 1F). Overall, based on the gene expression profiles, we identified three immune subtypes that were associated with clinical outcomes.

**Subtype-Specific Genes and Signaling Pathways in Diffuse Glioma**

We performed differential analyses to identify differentially expressed genes and signaling pathways specific to the three
identified subtypes. We assumed genes to be significantly differentially expressed when absolute log₂FC was >1.0 and FDR was <0.05 compared with the other subtypes. We then screened 4,293 genes, including 3,491 genes for subtype C1, 156 genes for subtype C2, and 646 genes for subtype C3; these were selected for KEGG analyses to identify the specific signaling pathways. It was confirmed that these differentially expressed genes in subtypes C1 and C3 were enriched for terms associated with different biological processes; however, both were found to be enriched for terms associated with the neutrophil-related pathway, including neutrophil chemotaxis and migration (Figures 2A, B). The set of differentially expressed genes in subtype C2 was not enriched for terms associated with any pathway. Subtype-specific genes were considered differentially expressed in one subtype but not in other subtypes. The top 50 differentially expressed genes of each subtype were selected as candidate molecular markers. We identified 108 subtype-specific markers, with 47 specific genes for subtype C1, 14 for subtype C2, and 47 for subtype C3 (Figure 2C). We additionally conducted t-SNE to decrease the dimensionality of the features in TCGA cohort, in which the three sample clusters were separated from each other (Figure 2D). The 108 subtype-specific signature genes were found and are shown in Figure 2E. The genes were differentially expressed in the three subtypes, indicating that these genes are significant indicators of these subtypes. Overall, we successfully identified signature genes and signature signaling pathways of the three subtypes.

**Characteristics of the Three Subtypes of Diffuse Glioma**

To identify clinical characteristics of the three subtypes of diffuse glioma, we examined conventional clinical variables, including age, gender, tumor grade, IDH mutation status, 1p19q codeletion status, and MGMT promoter status in TCGA cohort. The results indicated that the clinical characteristics differed significantly among the three immune subtypes of diffuse glioma (Table 1; χ² test, P < 0.05). In this study, subtype C1 had a higher histological grade than the other subtypes (χ² test, FDR < 0.0001). Mutation status of IDH, including IDH1, is a distinctive biomarker for glioma classification and prognostic assessment (28). The proportion of cases with wild-type IDH in the tumor was significantly higher in subtype C1 than in the other subtypes (χ² test, FDR < 0.0001, Figure 3A). These findings further explained why patients with subtype C1 had a dismal prognosis relative to the patients with other subtypes. In contrast, subtype C3 contained a slightly higher proportion of cases of WHO grade II than did the other subtypes (χ² test, FDR < 0.0001); meanwhile, the proportion of cases with mutant IDH1 in the tumor was significantly higher in subtype C3 than in subtypes C1 and C2 (χ² test, FDR < 0.0001, Figures 3A, B). The distribution of tumor grades and IDH1 mutation states in subtype C2 was intermediate between subtypes C1 and C3. At the same time, samples with the same grade were distributed across different subtypes, indicating heterogeneity of the same grade of glioma. Since the classification was based on immune-
related genes, we explored the characteristics of the microenvironment. The ESTIMATE approach was employed to infer the stromal- and immune-cell admixture using TCGA transcriptome data on diffuse glioma (22, 29). The stromal scores and immune scores were significantly higher ($P < 0.001$) in subtype C1 than those in the other subtypes (Figures 3C, D). Conversely, the stromal and immune scores were significantly lower in subtype C3 than in the other subtypes. Similarly, the characteristics of subtype C2 diffuse glioma were intermediate between subtypes C1 and C3 (Figures 3C, D). Overall, the characteristics of the three subtypes of diffuse glioma varied significantly.

**Correlation of Diffuse Glioma Subtypes With Immune Infiltration in The Cancer Genome Atlas Cohort**

Given the significant differences in immune scores among the three identified subtypes of diffuse glioma, we then investigated whether such subtypes are associated with immune infiltration. First, relative presence of 28 immune cell types was quantified...
using the GSVA package in R as previously described (24), and the results were presented in a heatmap (Figure 4A). After that, differential analyses were conducted to identify subtype-specific immune cells, which were defined as immune cells with a higher GSVA score in a given subtype relative to the other subtypes. There were significant differences in most of immune cell types between subtype C1 and the other subtypes (Figures 4B, D). Moreover, there were significantly higher abundance of 27 immune cell populations, except for eosinophils, in C1 compared with C2 or C3 (Figures 4B, D). In contrast, subtype C3 exhibited a reduction in these 27 immune cell populations and greater enrichment of eosinophils (Figures 4C, D). We also noted higher abundance of 25 immune cell types in subtype C2 relative to subtype C3 (Figure 4B).

We next assessed the abundance of six cell types—activated CD4⁺ T cells, activated CD8⁺ T cells, NK cells, macrophages, activated dendritic cells, and neutrophils—in the GSE16011 cohort (Figure 5). Consequently, the six immune cell populations were significantly more abundant in subtype C1 relative to subtypes C2 and C3. On the other hand, the abundance of these six immune cell populations was remarkably less in subtype C3 compared with that in the other subtypes. Macrophages play an important role in glioma maintenance and progression. By contrast, macrophages of the M1 phenotype (they have a potential to suppress tumor growth) are usually not present at a tumor site (30). We then investigated the correlation of the diffuse glioma subtypes with macrophage subtypes in TCGA cohort using the CIBERSORT algorithm from the TIMER online database. We found significant differences between C1 and the other subtypes, with the highest abundance of M2 macrophages in C1 and the lowest in C3 (Supplementary Figure 2). In addition, the CIBERSORT algorithm did not identify a significant difference in M1 enrichment among the three subtypes (Supplementary Figure 2). These results are in agreement with the immune- and stromal-score findings. Therefore, there were differences in the abundance of immune cells among the three subtypes according to the differences in immune-related genes.

### Differential Expression of Immune Checkpoint Molecules and Tumor Mutational Burden in The Cancer Genome Atlas Cohort

In the three subtypes, we investigated the expression of immune checkpoint genes that perform crucial functions in cellular immune regulation (31). Similar to the abundance of immune cells, the expression of most checkpoint genes, such as PD1, PD-L1, CTLA4, and B7H3, was found to be upregulated in subtype

### Table 1: Association of the three immune-related characteristics with clinical characteristics in TCGA cohort.

| Clinical Characteristics | Molecular subtypes (n, %) | p value |
|--------------------------|--------------------------|---------|
| Age                      |                          |         |
| <40y                     | 14(14.4)                 | 71(40.0) |
| >=40y                    | 82(84.5)                 | 92(51.7) |
| N/A                      | 1(1.0)                   | 15(8.4)  |
| Gender                   |                          |         |
| Female                   | 32(33.0)                 | 71(40.0) |
| Male                     | 64(66.0)                 | 91(51.1) |
| N/A                      | 1(1.0)                   | 15(8.4)  |
| Histology                |                          |         |
| Astrocytoma              | 5(5.2)                   | 34(19.1) |
| Oligodendrogloma         | 5(5.2)                   | 82(46.1) |
| Oligoastrocytoma         | 2(2.1)                   | 29(16.3) |
| Glioblastoma             | 84(86.8)                 | 18(10.1) |
| N/A                      | 1(1.0)                   | 15(8.4)  |
| Grade                    |                          |         |
| G2                       | 1(1.0)                   | 72(40.4) |
| G3                       | 11(11.3)                 | 73(41.0) |
| G4                       | 84(86.8)                 | 18(10.1) |
| N/A                      | 1(1.0)                   | 15(8.4)  |
| IDH status               |                          |         |
| Mutant                   | 80(82.6)                 | 43(24.2) |
| WT                       | 11(11.3)                 | 135(75.8)|
| N/A                      | 6(6.2)                   | 0(0)    |
| 1p/19q codeletion         |                          |         |
| Non-codel                | 2(2.1)                   | 77(43.3) |
| Codel                    | 93(95.8)                 | 101(56.7)|
| N/A                      | 2(2.1)                   | 0(0)    |
| MGMT promoter status     |                          |         |
| Unmethylated             | 44(45.3)                 | 27(15.2) |
| Methylated               | 32(33.0)                 | 146(82.0)|
| N/A                      | 21(21.6)                 | 5(2.8)  |

y, years; WT, wild-type; N/A, not available.
C1 compared with that in the other subtypes. By contrast, the expression of most checkpoint genes was downregulated in subtype C3 compared with that in the other subtypes. In addition, the expression of ligands corresponding to the checkpoint molecules, such as PD-L1/PD-L2 for PD1, CD86/CD80 for CTLA4, and TLT2 for B7H3, was significantly upregulated in subtype C1 compared with that in the other subtypes (Figure 6). The expression of B7H4, one of the checkpoint genes, was markedly downregulated in subtype C1 compared with that in subtypes C2 and C3 (Figure 6I). The expression of PD-L1 and numbers of tumor-infiltrating immune cells have been reported to be increased in GBM (32), in line with our findings. Another study has shown that TMB correlates with antitumor immunity and responses to immune checkpoint blockade in multiple tumor types (33). To further investigate the differences in somatic mutation frequencies among the three subtypes, we analyzed the total number of mutations after excluding samples with outlying values by means of the ‘outlier’ package in R. Our findings indicated that C1 was associated with a significantly higher mutation frequency than C2 and C3, notwithstanding a few C1 samples (Figure 7A). In addition, we analyzed correlations between TMB and the abundance of activated CD8\(^+\) T cells, and between TMB and the expression of PD-L1 and PD1 mRNA. The abundance of activated CD8\(^+\) T cells and the mRNA expression of PD-L1 and PD1 exhibited a consistently weak positive correlation with TMB values (Pearson’s correlation coefficient test, for activated CD8\(^+\) T cells, R = 0.337; for PD-L1, R = 0.235; for PD-1 R = 0.135, Figures 7B–D). IDH1, TP53, and ATRX were the three most frequently mutated genes; they are involved in glycolysis, the P53 pathway, and the G2/M checkpoint, respectively (Supplementary Figure 1). Hallmark genes of the three pathways were identified by mining of the Molecular Signatures Database (MsigDB). The mutation frequency of ATRX (16.2%) was significantly lower in the C1 subtype than that in the C2 (40.7%) and C3 subtypes (24.8%). In contrast, the mutation frequency of TP53 was significantly lower in the C3 subtype (34.8%) compared with the C1 subtype (40.5%) and C2 subtype (53.0%). Notably, the genes involved in glycolysis exhibited a higher mutation frequency relative those involved in other pathways (Figure 7E). Nevertheless, the three subtypes exhibited distinct mutational characteristics with respect to the three pathways.

**Diffuse Glioma Subtypes are Associated With Overall-Survival Prognosis in Different Grades of Glioma**

The above findings reveal that the three immune-related subtypes are associated with clinical outcomes. To confirm that the subtype can serve as an independent prognostic factor, we assessed the survival model in TCGA cohort using candidate independent variables (age, gender, grade, IDH status, and 1p/19q codeletion). Univariate Cox regression analysis revealed that the subtype was significantly related to an improved prognosis of patients with diffuse glioma (95% confidence interval 0.27–0.44, P < 0.0001, Figure 8A). In addition, multivariate Cox regression
analysis revealed that the subtype was a significant independent prognostic factor in patients with diffuse glioma, independently of age, gender, tumor grade, IDH mutation, and 1p/19q codeletion (95% confidence interval 0.59–0.93, P < 0.01, Figure 8B). These results collectively implied that the subtype is an independent prognostic indicator in patients with diffuse glioma. Both tumor grade and IDH mutation status are important independent prognostic factors of diffuse glioma. Kaplan–Meier survival curve was plotted to evaluate prognostic differences among the subtypes in LGG, higher-grade glioma (HGG), IDH wild-type glioma, and IDH-mutant glioma (Supplementary Figure 3). Significant prognostic
differences among the three subtypes were observed in LGG and IDH wild-type glioma, while no significant difference was found in HGG and IDH-mutant glioma groups.

**DISCUSSION**

In recent years, although some approaches regarding the immune-related classification of gliomas that rely on the gene expression profiles have been proposed, no consensus has been reached on the molecular classification of diffuse gliomas, including GBM. In this study, we used immune-gene profiles to identify three distinct subtypes of diffuse glioma. To identify diffuse glioma subtypes associated with immune infiltration and clinical features, we designed a diffuse glioma classification approach based on 2,498 immune-related genes retrieved from the ImmPort database. Thus, three subtypes of diffuse glioma (C1, C2, and C3) were identified (Figure 1). Furthermore, we assessed subtype-specific pathways and genes, immune infiltration, clinical characteristics, and prognostic values. Our results showed that subtype-specific genes in C1 and C3 subtypes are enriched in terms associated with neutrophil-related pathways (Figures 2A, B). Patients with subtype C1 had a remarkably higher histological grade, a greater frequency of wild-type IDH1 in the tumor, and higher stromal scores and immune scores than patients with subtypes C2 and C3 (Figure 3), and exhibited poor clinical outcomes. Moreover, five immune-cell populations (T cells, NK cells, macrophages, dendritic cells, and neutrophils) were significantly more abundant in the tumors of subtype C1 than those in the other subtypes. mRNA expression of most checkpoint proteins was found to be upregulated in subtype C1 compared with that in the other subtypes (Figure 6). Subtype C1 had a significantly lower mutation frequency of genes involved in glycolysis, the P53 pathway, and G2/M checkpoint (Figure 7E). Although the biological processes enriched in the set of subtype-specific genes of C3 are similar to those of C1, subtype C3 was characterized by a lower histological grade, lower frequency of wild-type IDH in the tumor, lower expression of immune checkpoint genes, lower abundance of five immune-cell populations, and lower stromal and immune scores than the other subtypes. Subtype C2 manifested clinical features intermediate between the other two subtypes. In addition, we found that the subtype is an independent prognostic indicator in patients with diffuse glioma (Figure 8). Overall, we noticed the heterogeneity of the immune microenvironment of diffuse gliomas of the same grade. This result partially explains why some patients with high-grade glioma have a poorer prognosis than those with low-grade glioma. Besides molecular differences, tumor-infiltrating immune cells play a critical part in the progression and treatment of glioma.

Immune cells are important components of the tumor microenvironment and perform a dual function of immunostimulation or immunosuppression, via which they either promote or inhibit the progression of tumors (34, 35). A better classification approach based on immune-related gene profiles is urgently needed for improving the efficacy of personalized immunotherapy. In this study, we found that subtype C1 contain higher abundance of immune cells, including macrophages and neutrophils. Proinflammatory cytokines and chemokines are secreted by tumor-associated macrophages (19). Tumor-associated macrophages and neutrophils are associated with a dismal prognosis in patients with diffuse glioma (36). Relevant studies have shown that patients with GBM with a high neutrophil-to-lymphocyte ratio exhibit poorer survival than those with the low ratio, probably...
because tumor-infiltrating neutrophils—by releasing such factors as neutrophil extracellular traps—drive the crosstalk between glioma progression and the tumor microenvironment (37). The results of these studies are consistent with our findings and partly explain why patients with subtype C1 with abundant neutrophils in the tumor have a poorer prognosis than patients with subtypes C2 and C3. In summary, we established that subtype C1 is typified by high levels of infiltration by macrophages and neutrophils, which may contribute to a poor prognosis.

Immune checkpoint receptors, including PD-1 and CTLA4, are expressed on the surface of immune cells, whereas the cognate ligands (PD-L1/PD-L2 and CD86/CD80) are expressed on the tumor cell surface. The expression of immune checkpoint receptors is commonly upregulated in the tumor microenvironment. Herein, it was demonstrated that immune checkpoint genes are differentially expressed in the three identified subtypes, in line with previous findings (38, 39). Additionally, subtype C1, with a higher proportion of GBM cases, showed higher expression of PD-L1 and PD-1 in our study. This result suggests that PD-1 checkpoint blockade can be used to identify subtype C1. Moreover, we found that PD-1 and CTLA4 are upregulated in more patients with subtype C1 GBM and are downregulated in subtype C3 GBM; these results are in agreement with the findings of another report (40). In the glioma subtypes identified here, the distribution of immune checkpoint genes was comparable to that of immune cells, including CD4+ T cells, activated CD8+ T cells, B cells, macrophages, dendritic cells, and neutrophils. Subtype C3 preferentially exhibited lower expression of immune checkpoint receptors and ligands such as PD-L1, PD-L2,
CD86, and CD80. Collectively, these findings suggest that subtype C1 diffuse gliomas are characterized by a more immunosuppressive microenvironment. This hypothesis is supported by our survival analysis results, which indicate that the prognosis of patients with subtype C1 is worse than that of patients with subtypes C2 and C3. An immunosuppressive tumor microenvironment is one of the main reasons underlying chemotherapy resistance and immunotherapy failure in patients with diffuse glioma. Recent studies have shown that patients with glioma have higher expression of some immunosuppression related genes, such as LGALS1 and IGFBP2, and blocking the expression of immune-inhibiting related genes can remodel the immunosuppression microenvironment (41, 42). Our study showed that patients with subtype C1 have high expression of immune checkpoint molecules in the tumor; hence, reshaping the immunosuppressive microenvironment by the blocking of immune checkpoint molecules may provide new insights into the immunotherapy for diffuse glioma and can offer a new molecular classification strategy for the accurate treatment of patients with diffuse glioma. Therefore, we can speculate that patients with subtype C1 may clinically benefit more from the blocking of checkpoint pathways. Judging by our results, certain immune cells (including CD8+ T cells and NK cells) that suppress tumor growth, exhibit high infiltration of subtype C1, which showed poor survival. These conflicting results suggest that the antitumor function of immune cells varies in diffuse glioma and is far more complex than previously expected. The presented immune subtyping was partially consistent with the histological grade of glioma, thereby indicating its effectiveness in terms of some aspects and its potential to supplement conventional glioma classification.
GBM patients with DNA damage repair defects may exhibit high mutation rates in the tumor that make the disease sensitive to immune checkpoint inhibitors (43). The current study showed that alterations of DNA damage repair may result in remodeling of the glioma microenvironment by modulating M2 polarization of the microglia (44). The three subtypes were found to have distinct mutation characteristics after the exclusion of outlying samples using the outlier package in R. Subtype C1 glioma has a significantly higher histological grade and mutation frequency than subtypes C2 and C3. Hypermutation in glioma is associated with CD8+ T cell enrichment (45). Therefore, we can theorize that more subtype C1 diffuse glioma patients are sensitive to treatment with immune checkpoint inhibitors than subtype C2 and C3 glioma patients. Some studies have revealed that major LGGs with no IDH mutations are molecularly and clinically similar to GBM (46). In our study, C1 had a significantly lower IDH1 mutation frequency, thereby partly explaining why patients with subtype C1 had a dismal prognosis. Subtype C2 is associated with a markedly higher IDH1, TP53, and ATRX mutation frequency than the other subtypes. The prognosis of patients with subtype C2 proved to be worse than that of patients with subtype C3. This contradicts the above conclusions, which indicates that immune subtypes reflect the prognostic mechanisms of glioma better than mutations.

CONCLUSIONS

We identified three immune-associated subtypes of diffuse glioma based on expression profiling of immune-related genes, and demonstrated the potential of the subtypes for immune checkpoint blockade. These three subtypes exhibit significant differences with respect to immune infiltration, immune checkpoint gene expression, and clinical characteristics. These findings provide novel insights into the design of immunotherapeutic strategies against diffuse glioma.

REFERENCES

1. GLASS Consortium. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. *Neuro Oncol* (2018) 20(7):873–84. doi: 10.1093/neuonc/noy020
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* (2005) 352:987–96. doi: 10.1056/NEJMoa043330
3. Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, et al. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. *Front Immunol* (2018) 9:2924. doi: 10.3389/fimmu.2018.02924
4. Martinez-Ricarte F, Mayor R, Martinez-Saez E, Rubio-Perez C, Pineda E, Cordero E, et al. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. *Clin Cancer Res* (2018) 24:2812–9. doi: 10.1158/1078-0432.CCR-17-3800
5. Aguila B, Morris AB, Spina R, Bar E, Scharer J, Vinkler R, et al. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme. *Cancer Lett* (2019) 462:33–42. doi: 10.1016/j.canlet.2019.07.018
6. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. The association between immune cell infiltration and clonal architecture in grade II and III gliomas. *Nat Genet* (2015) 47:458–68. doi: 10.1038/ng.3273

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

QZ, CR, and XJ conceived and designed the study and analyzed the data. The other authors performed the data analysis. QZ wrote the manuscript, and XY and WL revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Natural Science Foundation of China [grant No. 81472355 (to XJ); grant No. 81773179 and 81272972 (to CR)] and the Hunan Provincial Science and Technology Department [grant No. 2014FJ6006 (to XJ); grant No. 2016JC2049 and 2020JJ4771 (to CR)].

ACKNOWLEDGMENTS

We are sincerely grateful to those who created and maintained these public databases such as TCGA and GEO.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.586019/full#supplementary-material

7. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. *Neuro Oncol* (2016) 18:v1–v75. doi: 10.1093/neuonc/now207
8. Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. *Lab Invest* (2017) 97:498–518. doi: 10.1038/labinvest.2017.19
9. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer* (2012) 12:298–306. doi: 10.1038/nrc3245
10. Rape A, Ananthanarayanan B, Kumar S. Engineering strategies to mimic the glioblastoma microenvironment. *Adv Drug Delivery Rev* (2014) 79:80-172–83. doi: 10.1016/j.addr.2014.08.012
11. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, et al. The tumor microenvironment strongly impacts major transcriptional regulators and gene expression class of glioblastoma. *Am J Pathol* (2012) 180:2108–19. doi: 10.1016/j.ajpath.2012.01.040
12. Domingues P, González-Tablas M, Otero A, Pascual D, Miranda D, Ruiz L, et al. Tumor infiltrating immune cells in gliomas and meningiomas. *Brain Behav Immun* (2016) 53:1–15. doi: 10.1016/j.bbi.2015.07.019
13. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. *Nat Rev Clin Oncol* (2018) 15:422–42. doi: 10.1038/s41571-018-0003-5
14. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2015) 17:1064–75. doi: 10.1093/neuroonc/nou307

15. Tsurub PC, Harview CL, Yearley JH, Shinakui JP, Taylor DJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515:568–71. doi: 10.1038/nature13954

16. Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Zhang Y, et al. sva: Surrogate Variable Analysis. R package version 3.3.6. (2020)

17. Gravendeel LA, Koenen MC, Gevaert O, de Rooi JJ, Stubb A, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res (2009) 69:9065–72. doi: 10.1158/0008-5472.CAN-09-2307

18. Zhou H, Wang F, Tao P. t-Distributed Stochastic Neighbor Embedding Method with the Least Information Loss for Macromolecular Simulations. J Chem Theory Comput (2018) 14:5499–510. doi: 10.1021/acs.jctc.8b00652

19. Chiarugi P. Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancy. Oncoimmunology (2013) 2:e25563. doi: 10.4141/onci.25563

20. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 43:e47. doi: 10.1093/nar/gkv007

21. Yu G, Wang LG, Han Y, He QY, clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS (2012) 16:284–7. doi: 10.1089/omi.2011.0118

22. Yoshibara K, Shahmoradgoli M, Martinez E, Vegas R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 4:6216. doi: 10.1038/ncomms3612

23. Hänzelmann S, Castelo R, Guney I. GSVA: gene set variation analysis for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res (2017) 77:108–10. doi: 10.1158/0008-5472.CAN-17-0307

24. Morrow PA, Sverdlov D, Jiang T, Chen Y, Guo X, et al. A new landscape of tumor intrinsic subtypes defined by gene expression space. Cancer Res (2015) 75:1963–71. doi: 10.1158/0008-5472.CAN-14-3308

25. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 12:453–7. doi: 10.1038/nmeth.3337

26. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res (2017) 77:e108–10. doi: 10.1158/0008-5472.CAN-17-0307

27. Kramar A, Com-Nougue C. Estimation des courbes de survie ajustées [Estimate of adjusted survival curves]. Rev Epidemiol Sante Publique (1990) 38:49–52.

28. Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, et al. Residual lesions of gliomas are a better predictor of survival than histology. Neuro Oncol (2018) 20:7. doi: 10.1093/neo/cco217

29. Su J, Ma Q, Long W, Tang H, Wu C, Luo M, et al. LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas. Front Oncol (2019) 9:1083. doi: 10.3389/fonc.2019.01083

30. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 42:2177–27. doi: 10.1016/j.ejca.2006.01.003

31. Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, et al. Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res (2017) 77:1245–9. doi: 10.1158/0008-5472.CAN-16-1647

32. Ndoum EK, Wei J, Yaghhi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2016) 18:195–205. doi: 10.1093/neuonc/nov172

33. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowic SM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet (2018) 50:1271–81. doi: 10.1038/s41588-018-0200-2

34. Leom-Cabrera S, Schwertfeger KL, Terrazas LL. Inflammation as a Target in Cancer Therapy. Mediators Inflamm (2019) 2019:1971698. doi: 10.1155/2019/1971698

35. Su J, Long W, Ma Q, Xiao K, Li Y, Xiao Q, et al. Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Front Genet (2019) 10:1143. doi: 10.3389/fgene.2019.01143

36. Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, et al. Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res (2017) 23:6279–91. doi: 10.1158/1078-0432.CCR-16-2598

37. Zha CJ, Meng XQ, Li LL, Mi S, Qian D, Li ZW, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis. Cancer Biol Med (2020) 17:154–68. doi: 10.20892/j.issn.2095-3941.2019.0353

38. Hwang K, Koh EJ, Choi EJ, Kang TH, Han CH, Choe G, et al. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol (2018) 139:281–91. doi: 10.1007/s11060-018-2886-5

39. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 27:450–61. doi: 10.1016/j.ccell.2015.03.001

40. Liu F, Huang J, Liu X, Cheng Q, Luo C, Liu Z. CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int (2020) 20:7. doi: 10.1186/s12935-019-1085-6

41. Chen Q, Han B, Meng XQ, Duan CB, Yang CX, Wu ZY, et al. Immunogenic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma. Int J Cancer (2019) 145:517–30. doi: 10.1002/ijc.32102

42. Cai JQ, Chen Q, Cui YQ, Dong JW, Chen M, Wu PF, et al. Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. Oncoimmunology (2018) 7:e1426516. doi: 10.1080/20420203.2018.1426516

43. Le DT, Durham JM, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 357:409–13. doi: 10.1126/science.aan6733

44. Meng XQ, Duan CB, Pang HY, Chen Q, Han B, Zha CJ, et al. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. EBioMedicine (2019) 41:855–99. doi: 10.1016/j.ebiom.2019.01.067

45. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res (2017) 77:1245–9. doi: 10.1158/0008-5472.CAN-16-1647

46. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. Nat Engl J Med (2015) 372:2481–98. doi: 10.1056/NEJMoa1402121

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.